Abstract 129P
Background
There is no conclusion regarding the indications for No.10 LND in advanced proximal gastric cancer (PGC). We aimed to explore the best candidates for splenic hilar lymph node dissection (No.10 LND) from the perspective of long-term survival.
Methods
Data of 995 patients who underwent laparoscopic radical gastrectomy from January 2008 to December 2014 were analyzed. Five hundred sixty-four patients underwent No.10 LND (No.10D+ group); the other 431 patients did not receive No.10 LND (No.10D- group). Propensity score matching was applied to reduce the effects of observed confounding. Study end points were overall survival (OS) and disease-free survival (DFS).
Results
No.10 LN metastasis was associated with pT or pN in multivariate logistic analysis (P<0.05). Recursive partitioning analysis obtained 3 groups of patients with different risks of No.10 LN metastasis: low-risk group (pT1-3N0-1), the No.10 LN metastasis rate was 0; intermediate-risk group (pT4aN0-1, pTanyN2, pT1-3N3a), the rate was 6.5%; and high-risk group (pT1-3N3b, pT4aN3), the rate was 30.5%. After matching, stepwise stratification survival analysis showed that for stage IIIA PGC, the No.10D+ group had significantly better survival than the No.10D- group (5-year OS: 68.9% vs. 48.1%%, P=0.001; 5-year DFS: 66.3% vs. 41.2%, P=0.001). Comparison of recurrence patterns in stage IIIA PGC showed that the No.10D+ group had a significantly lower overall recurrence rate (26.4% vs. 50.6%, P=0.004) and distant metastasis rate (11.1% vs. 38.1%, P<0.001) than the No.10D- group.
Conclusions
Stage IIIA PGC may achieve the benefit of long-term survival from No.10 LND. For PGC with stage IIIB and IIIC, although the No.10 LN metastasis rate is high, No.10 LND does not result in survival benefits, and neoadjuvant therapy before surgery is recommended.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
360P - Number of lymph nodes examined was not an independent risk factor for the survival of patients with stage IA1-2 lung adenocarcinoma undergoing sublobar resection
Presenter: Zhenbin Qiu
Session: e-Poster Display Session
361P - Radiomic model predicting radiological response after thoracic stereotactic body radiotherapy regardless of tumor histology and staging
Presenter: Ben Man Fei Cheung
Session: e-Poster Display Session
362P - Integrative and comparative genomic analysis and immune microenvironment features of lung cancer patients with tuberculosis
Presenter: Xiaoling Xu
Session: e-Poster Display Session
363P - Genetic predisposition for pre-invasive lung adenocarcinoma manifesting as ground-glass nodules with family history of lung cancer
Presenter: Rui Fu
Session: e-Poster Display Session
364P - A deep learning model for the classification of lung cancer
Presenter: Gouji Toyokawa
Session: e-Poster Display Session
365P - Utilization of on-site pathology evaluation for lung cancer diagnosis in the Philippines’ National University Hospital
Presenter: Rich Ericson King
Session: e-Poster Display Session
367P - Detection of epidermal growth factor receptor mutations (EGFR-mut) from cell-free DNA in pleural effusion (PE-DNA) of patients with non-small cell lung cancer (NSCLC)
Presenter: Kirsty Lee
Session: e-Poster Display Session
368P - Real-world characteristics, treatment, and outcomes of stage III non-small cell lung cancer in Japan: SOLUTION study
Presenter: Haruyasu Murakami
Session: e-Poster Display Session
369P - The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
Presenter: Long Jiang
Session: e-Poster Display Session
371P - Real-world insights into treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): KINDLE study India analysis
Presenter: Kumar Prabhash
Session: e-Poster Display Session